We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Thinksmart Limited | LSE:TSL | London | Ordinary Share | AU000XINEAE8 | ORD NPV (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 28.50 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
22/2/2004 22:43 | phoenxbird glad I caught yo the other night. The Intercast has two entry levels. The method you logged in at was superjava designed fot dialup users the other method is a Hotcom download meant for broadband users. Very interesting day the next as the AFG AFD Ceo came on and there were 135 users on at once all with the potential to badger the CEO. His pitch was good and did no end of good to the share price. Pfofit takers probably brought it downn. Still holding at least for the short term. | whitebicycle | |
17/2/2004 13:56 | Many thanks. | phoenixbird | |
17/2/2004 13:40 | The chat button on the toolbar bar above. A hybrid chatroom that has presenters hosting the room during the day. Guests can text in or use a mike if available. Had a few CEOs using for a presentation followed by a Qand A session. Generally populated by small investors, a few traders and the oddball that comes on makes a few noises and leaves. Require a software download. | whitebicycle | |
17/2/2004 12:46 | Hi Whitebike. Excuse my ignorance but what exactly is Intercast? | phoenixbird | |
17/2/2004 10:45 | Checked out the site yesterday phoenixbird, quite impressed as I had bought blind on friday. Discussed on the Intercast and Patrica went through the fundamentals, no surprises. Told by source it was good for 160p, looking at it now I think its good for a bit more. I'll do more research on Permacol, thanks for the reply, Regards, WhiteBike. | whitebicycle | |
17/2/2004 10:17 | As you will have noted, very few purchases today have pushed the price up 11.5p (as at 10:15am). Tons of upside on this one due to shortage of stock. Check out the TSL website re: product portfolio. The Permacol product has huge potential and has been taken up by CR Bard (a $6bn company in the US). | phoenixbird | |
17/2/2004 10:11 | Thanks phoenixbird, entered it for the Intercast weekly comp, out in front at the moment, could win me a months worth of Level 2. | whitebicycle | |
16/2/2004 22:23 | There is a shortage of stock, shares are tightly held. Two purchases of 25,000 each on Friday afternoon (delayed transactions)have pushed up the price today. | phoenixbird | |
16/2/2004 16:05 | Bought these Friday on a tip.Now moving up on nil volume, is news expected? | whitebicycle | |
06/2/2004 14:37 | Movement over last two days... | muscapharoah | |
11/11/2003 15:43 | Movement has started though a bit late, however worth watching... Parv | parvez | |
10/10/2003 12:31 | FAirly positive write up in Shares mag although 'Only' a HOLD recommendation. Says that Zimmer deal was largely ignored by the markets and suggests that a new deal with Bard may be in the offing | ok,yah | |
09/10/2003 11:47 | Up today. There is a reasonable amount of interest in comparison with recent months. You only have to look at the chart to see the recent surge in the share price. Its a stock for the longer term not for short term traders | ok,yah | |
08/10/2003 10:03 | Not much interest in this stock at all at the moment. Share price hardly moves. | muscapharoah | |
07/10/2003 08:48 | Bit of background info: PermacolTM Porcine Collagen AN INNOVATION IN BODY REPAIR Just like machinery, our bodies need repairing from time to time as the result of accident, illness, body defect, or simply as we get older. To carry out such corrective operations, e.g. repair of hernia or waterworks, accident damage particularly on the face, breast reconstruction, removal of debilitating scarring after injury or previous surgery, etc., surgeons need materials which may be used safely inside the body. They must not be rejected, must be non-toxic, effective, and last a long time. Materials currently available to surgeons include synthetic products made from silicon or polymers, mesh, Teflon, and natural products taken mostly from human or animal tissue such as collagen, skin grafts, and fat. Unfortunately, synthetic products by their very nature may lead to irritation or rejection, and never become fully integrated inside the body. Given the choice, surgeons largely prefer to use the natural (biological) products, but they are broken down by the body's processes, so do not last long. PermacolTM - an innovation in surgical body repair Developed by UK scientists over the past 20 years from pigskin (which has a structure very close to human tissue), PermacolTM is the world's first biological surgical implant material which provides the answers to surgeons' needs. It is safe, non-toxic, and is accepted by the body - indeed, it allows ingrowth by tissue cells and blood vessels. It is not broken down and therefore enables the surgeon to provide a permanent, strong repair. In flat sheet format PermacolTM is very strong yet flexible, and may easily be sutured or stapled, e.g. in a hernia repair. PermacolTM has been pioneered by Tissue Science Laboratories, a new all-British biopharmaceutical company dedicated to the research and development of natural products for the repair and reconstruction of human tissue | ok,yah | |
30/9/2003 13:01 | Any views about this stock? | muscapharoah | |
30/9/2003 07:27 | This should move quickly on a bit of buying. | ok,yah | |
30/9/2003 06:37 | (Warsaw, Indiana and Aldershot, UK) -- Zimmer Holdings, Inc. (NYSE:ZMH) and Tissue Science Laboratories (LSE:TSL) today announced that they have entered into an exclusive, multi-year worldwide agreement to distribute an innovative, nonresorbable biological patch for the repair of rotator cuff injuries in the shoulder. The product, PermacolTM Surgical Implant, was developed and is manufactured by Tissue Science Laboratories plc Todays results sound very upbeat as well | ok,yah | |
24/9/2003 14:27 | Not much discussion on this thread nowadays but I think this might be due for a rise Panmure rate this as a strong buy with forecasts for 2004 for earnings per share of 14.01p vs current share price of 86p. Has been ticking up slightly of late. The share has barely moved for a long time after almost halving in the bear markets yet the company remains upbeat and says it will not need funding again before profitability. | ok,yah | |
21/3/2002 10:43 | up 1p, i wonder if this will be start of another move north, seems good so far anyway... watching | oneliner | |
11/3/2002 08:34 | RNS Number:7043S Tissue Science Laboratories PLC 11 March 2002 11 March 2002 Preliminary Results for the year ended 31 December 2001 Tissue Science Laboratories plc ('TSL'), the medical devices company specialising in human tissue replacement and repair products derived from porcine dermis, today announces its Preliminary Results for the year ended 31 December 2001. Financial highlights - Successful flotation in December 2001 on the Alternative Investment Market which raised £10 million, before expenses - Turnover increased to £1.7 million (8 months to 31 December 2000: £0.1 million), primarily as a result of sales of PermacolTM Surgical Implant commencing in the US in April 2001 - Loss for the year of £3.4 million (8 months to 31 December 2000: £1.4 million) in line with expectations - Net funds at the year end of £8.4 million (2000: £0.1 million) Operational highlights - Positive progress being made with CR Bard Inc. in the urology and gynaecology market in the US and Europe, with sales of PermacolTM Surgical Implant progressing well - Appointment of Mike Waller as VP Sales and Marketing, for North America and the strengthening of the Sales and Marketing team for Europe - In January 2002, FDA approval received for PermacolTM Surgical Implant for Head and Neck applications; the Company is actively seeking a distribution partner in this area - A new manufacturing facility is being built to meet future capacity requirements and to bring current sub-contract facilities in-house. Completion expected mid 2002. - Commercial launch of PermacolTM Injectable (Urethral Bulking Agent) in Europe is expected in the second half of 2002. Commenting on the results, Martin Hunt, CEO of TSL, said: "Our strategy remains focused on the commercialisation of our technology and the development of products which address the opportunities identified in our target markets. There is still much to achieve, but we are looking forward to meeting the challenges ahead. Current trading is in line with expectations and we remain confident that we have laid the foundations of a first class medical devices company." -Ends- Enquiries: TSL plc Tel: 01252 333 002 Martin Hunt, Chief Executive Financial Dynamics Tel: 020 7831 3113 Melanie Toyne-Sewell / Fiona Noblet REVIEW FOR THE YEAR INTRODUCTION These are the first results for TSL plc as a public company after our successful flotation on the Alternative Investment Market ('AIM') in December 2001, when conditions in the financial markets were difficult. Against this background, the market responded positively to our offering and we were able to raise the funds required to finance our future development. We will be investing the proceeds in human clinical studies for our development products, a new manufacturing facility to support our planned requirements and commercial expansion in both US and Europe. FINANCIAL PERFORMANCE At flotation, the Company raised £10 million, before expenses, via a placing which valued the Company at £32.3 million. Additional fund raising activities during the year included two share offers in March and September which raised £1.7 million in total, and a £2.0 million bridging facility in the form of a convertible redeemable loan note. Since flotation, £1.2 million of the loan note has been repaid with the remaining £0.8 million converted into ordinary shares. Turnover for the year was significantly increased at £1.7 million (8 months ended 31 December 2000: £0.1 million) following the launch of PelvicolTM by CR Bard Inc. ('Bard') in the US in April 2001. The loss for the year after exceptional items of £3.4 million (8 months ended 31 December 2000: £1.4 million) was in line with expectations and reflects increased product development expenditure and infrastructure costs in manufacturing, marketing and administration. The exceptional operating charges relate to payments of £130,000 made to secure the assignment to the Company of patent rights over our core technology and £54,241 in respect of flotation costs not chargeable to the share premium account. In addition, £238,653 of exceptional costs in relation to the £2.0 million bridging loan have been reported within interest payable and similar charges. The basic loss per share of 25.6p compares with 13.8p for the 8 months to 31 December 2000. The balance sheet at the year end showed a solid cash position of £8.7 million (net funds of £8.4 million) as a result of the fund raising at flotation. OPERATIONAL REVIEW The market The market opportunity for our existing and development products is significant. The soft tissue implant market is c. $1.0 billion worldwide and is growing rapidly, partly as a result of the demand by surgeons to use new materials that offer real benefits over what is currently available. Concerns over the use of existing bovine and cadaver-sourced products on safety grounds also offer an opportunity for our technology. In addition, during 2002, we expect changes to be made by the European regulatory authorities in the way bovine-sourced materials are regulated to reflect their risk profile. Within the total soft tissue implant market, we are targeting for 2002 a number of sectors with PermacolTM Surgical Implant, namely: - Urology/Gynaecology - immediate market potential $165m (Figures for the US market only) - Head & Neck - immediate target market in excess of $60m (Figures for the US market only) - General surgery - market potential $120m (Figures for the US market only) Sales and marketing Sales strategy Our strategy for PermacolTM Surgical Implant is to operate directly in the UK, and through distribution partners in our other target markets in the US and Europe. Our first such partnership is with Bard in the field of urology and gynaecology. PelvicolO (the Bard trade name) was launched in Europe in April 2000 and in the US in April 2001. Bard is a leading urology company with the critical mass and reputation in the field to achieve rapid market penetration, and the partnership is progressing well. In the US, in parallel with our strategy in urology, we are targeting other specific applications of our technology into market segments where we can differentiate the product from competitors. Specifically, we are focusing on applications in the area of head and neck surgery and hernia repair where the characteristics of the product are especially appropriate. To access these sectors we intend to take a diversified approach to distribution. For head and neck surgery, we are currently seeking a distribution partner with an established market presence. In order to target specific areas of general surgery, such as the hernia repair market, we intend to use commission-only sales personnel to commence selling the product in the second half of 2002. In Continental Europe, we are actively seeking national distributors with existing, complementary product ranges to promote our technology across a variety of surgical applications referred to above, excluding gynaecology / urology applications which are covered by the Bard partnership. In the UK, we have our own sales force which we have recently increased to five. This means that we now have national coverage for the first time. Access to surgeons who specialise in each of the surgical applications we are targeting, is essential to the selling process. Introduction of a product such as PermacolTM Surgical Implant requires the sales team to identify opinion leaders and use their acceptance of the product to influence other potential users. Through Bard and our own sales team, we are developing support programmes to enhance our market penetration using surgeons who have converted to routine usage of PermacolTM and we will continue to build on this approach as we enter the new sectors we have targeted. Sales and marketing infrastructure To support our commercial expansion, we have an office in the UK. Since flotation, we have also opened a small sales office in Atlanta, USA - this office is now up and running and will provide a base for the expansion of sales efforts in that territory. Since the year end, we have also strengthened the sales team. In January 2002, Mike Waller was appointed Vice President Sales & Marketing, North America. He joined TSL from Bard Urological Division where he was Senior Marketing Manager with responsibility for the launch of PelvicolO in the US. Mike was instrumental in influencing key opinion leaders to adopt PelvicolO in the North American urological market. Other senior appointments made from within TSL include, John Brannigan Sales and Marketing Director for Europe, and Rob Sawyer who has been appointed Head of Marketing for Europe. Current trading In 2001, we experienced strong growth in the US and Europe; the characteristics of the product, have been well received by the market, in particular, in the US market since its launch in April 2001. Approximately 76% of total sales were generated in the US. Since the year end, we have continued to see our US and European sales growth continue according to plan, both through Bard and via our own team in the UK. Trading is progressing in line with expectations. Manufacturing To date, manufacturing operations have been carried out via subcontract arrangements under the direct supervision of TSL personnel. We are investing £1.5 million of the proceeds of the flotation in our own manufacturing facility, located in premises immediately adjoining those of our current subcontract manufacturer. This project is now well underway and once complete, this development will enable us to bring our manufacturing operations in-house. As part of this process, we have agreed the transfer of certain personnel from our current subcontractor which will mean that expertise and know-how that has been developed to date will not be lost to the Company. This project is planned for completion in the second half of 2002. Peer recognition TSL is working with surgeons across a number of disciplines to publish papers and write up case studies on the use of PermacolTM Surgical Implant in human tissue repair. Recent examples include product usage in abdominal repair, paediatric applications, maxillofacial procedures and pelvic floor repairs. We are also working with a number of academic institutions to further develop the applications of our core technology. We will update shareholders on progress going forward. Regulatory affairs Our regulatory workload remains high as a result of our product development activities and planned manufacturing facility. This includes submissions to the US Food and Drug Administration ('FDA') for our injectable product being developed to treat female stress incontinence and preparatory work for the same regulatory pathway for the cosmetic reconstruction injection and submissions to the European authorities for the latter product. In addition, our new manufacturing facility must be validated and approved to meet US and European standards. With this in mind, we have recruited an experienced Regulatory Affairs manager from within the healthcare industry. We will retain our European and US consultants for strategic advice, but we will bring the majority of the regulatory work in-house. This will increase our efficiency and reduce the overall cost of the regulatory function. New product development The current focus for development is to produce injectable variants of our core technology. PermacolTM Surgical Implant (Urethral Bulking Agent) We are targeting the female stress incontinence market, an area of significant unmet need with an estimated 7.7 million sufferers in the US. Our product is currently undergoing human clinical studies in Europe. Although already possessing a CE mark allowing us to sell the product in Europe, we require Pre-Marketing Approval (PMA) in order to launch in the US in 2004. These clinical evaluations are a key element of our submission to the FDA. In addition, we are conducting evaluations of the product to provide marketing data to support its commercial launch in Europe in the second half of 2002. The next stage of development activity for this product is to move from pilot scale to commercial scale manufacture. PermacolTM Surgical Implant Injectable (CR) This version of our injectable product which is being designed for use in cosmetic reconstruction and facial augmentation is at an earlier stage of development. As with the urethral bulking agent, the regulatory pathway for the US market is a PMA and launch is not anticipated before 2004. The market for cosmetic augmentation is substantial - in the US, it has a potential value of $540 million, and it is liable to grow rapidly as the wealthy western population ages. Board appointments During the year (prior to the flotation), a number of key appointments were made. John Hamer joined the Company in January 2000 and was appointed as Director of Scientific Affairs in May 2001. David Jennings stepped up to the Board as Finance Director in September 2001. David Lindop was appointed as a non-executive director in November 2001. Currently, the Board consists of three executive directors, three non-executive directors and a non-executive chairman. Outlook Our strategy remains focused on the commercialisation of our technology and the development of products which address the opportunities identified in our target markets. During 2002, we are seeking to open further sales and distribution channels with respect to new applications and geographical locations. We will also continue to invest in building the management team that will be able to deliver rapid growth and a sustainable increase in value to shareholders. There is still much to achieve, but we are looking forward to meeting the challenges ahead. Current trading is in line with expectations, and we remain confident that we have laid the foundations of a first class medical devices company. Patrick Paul Martin Hunt Chairman Chief Executive Tissue Science Laboratories plc Consolidated Profit & Loss Account for the Year Ended 31 December 2001 Pro-forma Year ended Year ended 8 months ended 31 December 31 December 31 December 2001 2000 2000 Note (Audited) (Unaudited) (Audited, restated) £000s £000s £000s ______ ______ ______ TURNOVER 4 1,706 432 112 Cost of sales (1,512) (415) (313) ______ ______ ______ Gross profit / (loss) 194 17 (201) Selling & distribution costs (302) (135) (80) Administrative expenses Research and development costs (1,293) (795) (616) Other administrative expenses (1,522) (767) (568) Exceptional administrative expenses 5 (184) - - ______ ______ ______ (2,999) (1,562) (1,184) ______ ______ ______ Operating loss (3,107) (1,680) (1,465) Interest receivable 28 39 35 Interest payable and similar charges Bank and finance lease interest (54) (3) (1) Exceptional finance costs 5 (239) - - ______ ______ ______ (293) (3) (1) ______ ______ ______ RETAINED LOSS ON ORDINARY ACTIVITIES BEFORE AND AFTER TAXATION (3,372) (1,644) (1,431) ______ ______ ______ Basic loss per ordinary shares 6 25.6p N/a 13.8p Diluted loss per ordinary share 6 25.7p N/a 13.9p All amounts relate to continuing operations There were no recognised gains and losses for the current or preceding period other than those included in the profit and loss account. There is no difference between the retained loss on ordinary activities before or after taxation for the period stated above and their historical cost equivalents. No dividend has been paid or is payable in either the current or prior periods. The prior year adjustment is disclosed in note 2. An unaudited pro-forma profit and loss account has been included for the year ended 31 December 2000 for the purposes of comparison. This pro-forma information is based on management accounts, which have not been subject to audit. Tissue Science Laboratories plc Consolidated Balance Sheet as at 31 December 2001 31 December 31 December 2001 2000 (Audited) (Audited, restated) £000s £000s ______ ______ FIXED ASSETS Tangible assets 857 530 CURRENT ASSETS Stocks 172 57 Debtors 875 159 Cash at bank and in hand 8,711 160 ______ ______ 9,758 376 ______ ______ CREDITORS: amounts falling due within one year (1,925) (521) ______ ______ NET CURRENT ASSETS/(LIABILITIES) 7,833 (145) ______ ______ TOTAL ASSETS LESS CURRENT LIABILITIES 8,690 386 ______ ______ CREDITORS: amounts falling due after more than one year (176) (16) ______ ______ NET ASSETS 8,514 369 ______ ______ CAPITAL AND RESERVES Called up share capital 2,212 1,060 Share premium account 12,477 2,157 Shares to be issued 46 - Merger reserve 545 545 Profit & loss account (6,766) (3,393) ______ ______ EQUITY SHAREHOLDERS' FUNDS 8,514 369 ______ ______ Tissue Science Laboratories plc Consolidated Cash Flow Statement for the year ended 31 December 2001 Year ended 8 months ended 31 December 31 December 2001 2000 Note £000s £000s ______ ______ Net cash outflow from operating activities 7 (2,274) (1,220) ______ ______ Returns on investment and servicing of finance 8 (265) 33 ______ ______ Capital expenditure and financial investment 8 (626) (290) ______ ______ Cash outflow before use of liquid resources and financing (3,165) (1,477) ______ ______ Financing Net cash inflow/(outflow) from financing 8 11,720 (3) ______ ______ Increase/(decrease) in cash in the year 8,555 (1,480) ______ ______ RECONCILIATION OF NET CASH FLOW TO MOVEMENT IN NET FUNDS Increase/(decrease) in cash in the year 8,555 (1,480) ______ ______ Cash (inflow)/outflow from movement in debt and lease financing (249) 3 Change in net funds / (debt) resulting from cash flows 8,306 (1,477) New finance leases - (28) Currency translation difference (5) 4 ______ ______ Movement in net funds / (debt) in the year 8,301 (1,501) ______ ______ Net funds brought forward 134 1,635 ______ ______ Net funds carried forward 8,435 134 ______ ______ Tissue Science Laboratories plc Statement of Total Recognised Gains and Losses For the year ended 31 December 2001 Year ended 8 months ended 31 December 31 December 2001 2000 Note (Audited) (Audited, Restated) £000s £000s ______ ______ Loss for the financial year (3,372) (1,431) Total recognised gains and losses in the period (3,372) (1,431) Prior period adjustment 2 (1,039) ______ Total recognised gains and losses since the last annual report (4,411) ______ Notes 1 ACCOUNTING POLICIES AND BASIS OF PREPARATION The financial information set out in this announcement does not constitute the Company's statutory accounts for the year ended 31 December 2001 or for the eight months ended 31 December 2000, but is derived from those accounts. Statutory accounts for the eight months ended 31 December 2000 have been delivered to the Registrar of Companies and those for the year ended 31 December 2001 will be delivered following the Company's annual general meeting. The auditors have reported on those accounts; their reports were unqualified and did not contain statements under s237(2) of (3) Companies Act 1985. The financial statements for the year ended 31 December 2001 have been prepared after taking into account FRS 18 Accounting Policies for the first time. The adoption of FRS 18 has not had a material impact on the Company's financial statements. The accounting policies adopted are consistent with those adopted in the previous period, except for the restatement detailed in note 2. 2 RESTATEMENT OF COMPARATIVES AND PRIOR YEAR ADJUSTMENT The following changes have resulted in the restatement of comparatives and a prior year adjustment. The adoption of merger accounting on consolidation has resulted in the creation of a merger reserve, the write-off of purchased goodwill has resulted in an increase of retained losses brought forward and the more appropriate assessment of risks attached to leases which has resulted in the capitalisation of leases previously treated as operating leases. As a result of the changes in policy, the comparatives have been restated as follows: Consolidated Balance Sheet Retained losses Intangible Tangible Merger brought fixed assets fixed assets Creditors reserve forward £000s £000s £000s £000s £000s ______ ______ ______ ______ ______ 31 December 2000 as previously reported 494 504 511 - (2,353) Merger accounting and goodwill write-off (494) - - 545 (1,039) Capitalisation of leases - 26 26 - - ______ ______ ______ ______ ______ 31 December 2000 restated - 530 537 545 (3,392) ______ ______ ______ ______ ______ Operating Interest Loss for the | oneliner | |
06/2/2002 00:46 | Could be interesting, recently tipped, not sure if there's froth in the price or not but I have had a punt. They have some approvals, check RNS via Quotes page. Do your own research please, feel free to discuss below pros/cons. | oneliner |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions